SVB Leerink Begins Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX)

SVB Leerink began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $5.00 price target on the biopharmaceutical company’s stock.

LXRX has been the topic of a number of other reports. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 23rd. StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a research note on Monday, April 15th.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX stock traded up $0.04 on Tuesday, hitting $1.74. The company had a trading volume of 5,858,774 shares, compared to its average volume of 4,359,358. Lexicon Pharmaceuticals has a twelve month low of $0.92 and a twelve month high of $3.79. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. The firm has a market cap of $428.46 million, a P/E ratio of -2.17 and a beta of 1.38. The company has a 50-day moving average price of $2.12 and a 200-day moving average price of $1.74.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. As a group, equities research analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. TIAA Trust National Association purchased a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at approximately $29,000. SG Americas Securities LLC acquired a new stake in Lexicon Pharmaceuticals in the third quarter valued at approximately $64,000. Swiss National Bank lifted its stake in Lexicon Pharmaceuticals by 4.4% in the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 10,300 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Lexicon Pharmaceuticals by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 22,043 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 24,400 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.